心臟标记测试市场：规模、细分市场、份额、监管、报销、到 2033 年的预测

心臟标记检测可测试疑似或已有ACS 或HF 患者的某些心臟标记水平，如肌钙蛋白、脑钠□(BNP) 和肌酸激□心肌带(CK-MB)。用于确定是否患有ACS 或HF。正在上升或下降。 肌钙蛋白通常被认为是 ACS 的黄金标准心臟标记物，并且往往被纳入所有测试策略中。 然而，在美国，肌钙蛋白和 CK-MB 的组合是最常见的测试方法。 最后，大多数心臟标记检测方案往往包括三个（而不是两个）时间点，特别是 CK-MB。 除了肌钙蛋白和 CK-MB 之外，还可以对 ACS 患者进行 BNP 和 NT-proBNP 检测。 因为多项临床研究表明，BNP 和 NT-proBNP 可预测患者死亡率和长期临床结果。

心臟标记检测模型包括肌钙蛋白检测、肌钙蛋白临床检测、肌钙蛋白POC检测、脑钠尿□（BNP）检测、脑钠尿□（BNP）临床检测、脑钠□（BNP ）POC等测试、肌酸激□心肌带 (CK-MB) 测试和其他心臟标记 POC 测试（CK-MB POC 测试、包括肌钙蛋白、BNP 和 CK-MB 的心臟组合测试）。

本报告深入探讨了全球心臟标记检测市场，包括竞争格局、SWOT 分析、至 2033 年的市场预测、COVID-19 的影响、区域和国家趋势等。我是。

目录

目前心臟标记测试和竞争格局

• 对主要产业趋势的见解
• 2015 年至 2033 年心臟标记测试各细分市场的市场总收入及市场前景
• 有关数量、平均售价和市场价值的详细数据

全球、区域与国家见解

• 心臟标记检测市场的SWOT分析
• 心臟标记测试市场的竞争动态洞察与趋势
• 各国医疗保健系统概览
• 按国家/地区划分的报销政策
• 各国医疗科技的监管状况

Abstract

Cardiac Marker Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Cardiac Marker tests market for the year 2020 and beyond. Cardiac Marker testing is used to determine whether levels of specific cardiac markers such as troponin, brain natriuretic peptide (BNP), or creatine kinase - myocardial band (CK-MB) have risen or fallen in suspected and/or existing ACS and HF patients. In general, troponin is considered the gold-standard Cardiac Marker for ACS and tends to be incorporated into all testing strategies. Despite this however, a combination of troponin and CK-MB remains the most common testing strategy employed in the US. Finally, most Cardiac Marker testing protocols tend to include three (not two) timepoints, especially those that include CK-MB. In addition to troponin and CK-MB, BNP and NT-proBNP tests are also sometimes performed in ACS patients as several clinical studies have indicated that they are predictive of patient mortality and long-term clinical outcome.

Cardiac Marker Tests model include Troponin Tests, Troponin Laboratory Tests, Troponin Point of Care (POC) Tests, Brain Natriuretic Peptide (BNP) Tests, Brain Natriuretic Peptide (BNP) Laboratory Tests, Brain Natriuretic Peptide (BNP) Point of Care (POC) Tests, Creatine Kinase - Myocardial Band (CK-MB) Tests and Other Cardiac Marker POC tests (CK-MB POC tests and Cardiac Panel tests which include troponin, BNP, or CK-MB) as sub-segments.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Cardiac Marker Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Cardiac Marker Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Cardiac Marker Tests market.
• Competitive dynamics insights and trends provided for Cardiac Marker Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Quidelortho Corp, F. Hoffmann-La Roche Ltd, Siemens AG, bioMerieux SA, Danaher Corp, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

• CMO executives who must have deep understanding of the Cardiac Marker Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

• Understand the impact of COVID-19 on Cardiac Marker Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Cardiac Marker Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Cardiac Marker Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Cardiac Marker Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.